$AVNR News U.S. stock futures cut rise after retail sales

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 2:06 PM

$AVNR News

U.S. stock futures cut rise after retail sales 7:53 a.m. Aug. 13, 2013 - Barbara Kollmeyer
Cree, Flowers Foods in focus Tuesday 7:42 a.m. Aug. 13, 2013 - Wallace Witkowski
Yum Brands shares drop on sour China sales 4:23 p.m. Aug. 12, 2013 - Wallace Witkowski
Avanir to promote Merck's diabetes drug Januvia 3:48 p.m. Aug. 12, 2013 - MarketWatch.com
Avanir shares rise after hours on license deal 5:29 p.m. July 2, 2013 - Wallace Witkowski
Avanir, OptiNose enter N. America licensing deal 4:27 p.m. July 2, 2013 - MarketWatch.com
7 gut checks before the stock market's opening bell 5:43 a.m. April 29, 2013 - Shawn Langlois
Avanir Pharmaceuticals shares down 3% 9:37 a.m. Nov. 17, 2010 - Nick Godt
Monday’s biggest gaining and declining stocks 4:25 p.m. Nov. 1, 2010 - Laura Mandaro
Avanir and Allergan lead drug stocks 12:55 p.m. Nov. 1, 2010 - Val Brickates Kennedy
Avanir leads drug stocks north 9:06 a.m. Nov. 1, 2010 - Val Brickates Kennedy
Rexahn, Avanir gain; Sequenom falls 12:32 p.m. April 7, 2010 - Val Brickates Kennedy
Avanir, Opexa gain ahead of presentations 2:16 p.m. April 6, 2010 - Val Brickates Kennedy
Avanir shares jump 10% in pre-market action 8:27 a.m. April 6, 2010 - Val Brickates Kennedy
Drug stocks pressured by J&J report; Avanir jumps 12:49 p.m. Oct. 13, 2009 - Val Brickates Kennedy
Avanir, Acorda move on MS drug updates 2:51 p.m. Oct. 9, 2009 - Val Brickates Kennedy
Tuesday's biggest gaining and declining stocks 5:10 p.m. Aug. 11, 2009 - MarketWatch
Avanir soars and Javelin sinks on drug studies 12:15 p.m. Aug. 11, 2009 - Val Brickates Kennedy
Avanir Pharmaceuticals shares up 85% 8:41 a.m. Aug. 11, 2009 - Nick Godt
Avanir climbs on Phase III Zenvia trial success 6:31 a.m. Aug. 11, 2009 - Steve Goldstein

Mid-Afternoon Market Update: Markets Falling as Smith & Wesson Continues to Rise on Earnings 3:02 p.m. Dec. 11, 2013 - benzinga.com
Mid-Day Market Update: Smith & Wesson Gains On Upbeat Profit; LabCorp Shares Decline 11:29 a.m. Dec. 11, 2013 - benzinga.com
Summer Street defends Avanir after trial miss 10:38 a.m. Dec. 11, 2013 - Seeking Alpha
Mid-Morning Market Update: Markets Fall; Joy Global Profit Misses Estimates 10:37 a.m. Dec. 11, 2013 - benzinga.com
Avanir Reports Wider Loss - Analyst Blog 10:37 a.m. Dec. 11, 2013 - Zacks.com
Zacks #5 Rank Additions for Wednesday - Tale of the Tape 9:30 a.m. Dec. 11, 2013 - Zacks.com
Morning Market Losers 9:05 a.m. Dec. 11, 2013 - benzinga.com
Benzinga's Top #PreMarket Losers 7:34 a.m. Dec. 11, 2013 - benzinga.com
Benzinga's Top Downgrades 7:13 a.m. Dec. 11, 2013 - benzinga.com
Wednesday’s Biggest Stock Losers – AVNR, OPK and More 6:19 a.m. Dec. 11, 2013 - InvestorPlace.com
10-K: AVANIR PHARMACEUTICALS, INC. 6:09 a.m. Dec. 11, 2013 - Edgar Online - (EDG = 10Q, 10K)
Avanir's CEO Discusses F4Q 2013 Results - Earnings Call Transcript 8:08 p.m. Dec. 10, 2013 - Seeking Alpha
Avanir -13.8% AH, AVP-923 misses primary efficacy endpoint in phase II trial 5:36 p.m. Dec. 10, 2013 - Seeking Alpha
Q4 2013 AVANIR PHARMACEUTICALS Earnings Conference call (Webcast) 4:25 p.m. Dec. 10, 2013 - Seeking Alpha
Earnings Scheduled For December 10, 2013 4:14 a.m. Dec. 10, 2013 - benzinga.com
An Analysis Into Avanir Pharmaceuticals Neutralizes Concern And Reveals Potential 10:44 a.m. Dec. 9, 2013 - Seeking Alpha
Avanir Pharmaceuticals' CEO Presents at 25th Annual Piper Jaffray Health Care Conference (Transcript) 12:26 p.m. Dec. 4, 2013 - Seeking Alpha
Avanir Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference (Transcript) 11:43 a.m. Dec. 3, 2013 - Seeking Alpha
AVNR January 2015 Options Begin Trading 10:59 a.m. Nov. 8, 2013 - TheStreet.com
Insider Trading Alert - AVNR, ALK, BIIB, VRX And RAI Traded By Insiders 11:15 a.m. Nov. 6, 2013 - TheStreet.com

Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health 8:00 a.m. Today - PR Newswire
Technical Research on Equities: Zoetis, Actavis, Avanir Pharma, and Salix Pharma 8:00 a.m. Today - PR Newswire
Important Stocks Scan List: Nokia Corporation, BlackBerry Ltd, Sprint Corporation, Avanir Pharmaceuticals 9:03 a.m. Dec. 11, 2013 - ACCESSWIRE
Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results 4:00 p.m. Dec. 10, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Results for Phase II PRIME Study 4:00 p.m. Dec. 10, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Date of Fiscal 2013 Fourth Quarter Financial Results and Conference Call 8:00 a.m. Dec. 3, 2013 - GlobeNewswire
Avanir Pharmaceuticals to Participate in Two Conferences in December 8:30 a.m. Nov. 26, 2013 - PR Newswire
Stock Price Update, Recognitions, and Grant of Stock Options - Research Report on Cyberonics, Hill-Rom Holdings, Bio-Reference Laboratories, Avanir Pharmaceuticals, and ImmunoGen 8:00 a.m. Nov. 21, 2013 - PR Newswire
Before the Bell Scans: Zoetis Inc., Avanir Pharma, Actavis PLC, and Salix Pharmaceuticals Ltd 8:01 a.m. Nov. 13, 2013 - PR Newswire
Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares 8:00 a.m. Nov. 11, 2013 - PR Newswire
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 4:00 p.m. Nov. 8, 2013 - PR Newswire
Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information 7:30 a.m. Oct. 29, 2013 - PR Newswire
Recognitions, Patent Issuance, Financial Results, Upcoming Investor Conferences and Update on ClinicalTrial - Research Report on Stereotaxis, Immunomedics, Novadaq, Avanir, and Raptor Pharmaceuticals 8:00 a.m. Oct. 28, 2013 - PR Newswire
Technical Study: Zoetis Inc., AVANIR Pharma Inc., Actavis plc, and Salix Pharma Ltd 8:18 a.m. Oct. 24, 2013 - PR Newswire
Avanir Pharmaceuticals to Host Investor Day on October 29, 2013 7:30 a.m. Oct. 23, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease 7:30 a.m. Oct. 22, 2013 - PR Newswire
Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3:15 p.m. Oct. 4, 2013 - PR Newswire
Today's Technical View: Avanir Pharmaceuticals Inc., Warner Chilcott PLC, Actavis Inc., and Dynavax Technologies Corp. 10:48 a.m. Oct. 1, 2013 - PR Newswire
Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache" 7:30 a.m. Sept. 20, 2013 - PR Newswire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Avanir Pharmaceuticals, Inc. 7:30 a.m. Sept. 16, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...